Latest From Biotech Now

Bioterrorism: Ten Years Later

Report Card Graphic 10 11 11

By Bob Graham, Jim Talent, Randy Larsen & Lynne Kidder of The WMD Center Ten years ago this week, while still in shock from the unspeakable horrors of 9/11, Americans were learning of a new threat—bioterrorism. As it turns out, the anthrax letters of October 2001 were a relatively small incident, in which 22 were infected and five died. Other than the psychological aspects and the costs of cleanup (in excess of $500 million), the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Boosting Investment in Biotech

Biofuel Research

The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO’s New Personalized Medicine and Diagnostics Working Group

Researcher

The Biotechnology Industry Organization (BIO) represents a diverse portfolio of companies throughout the continuum of personalized medicine. These companies include those that develop therapeutic and diagnostic products, as well as research tools companies that drive innovation in this area. With broad member representation from across the drug, biologic, diagnostic and research tool industries, BIO is uniquely positioned to serve as industry’s key voice on personalized medicine issues. As part of an effort to better utilize Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotechnology Delivers Medical Discoveries to Benefit Women Facing Breast Cancer

Marc S. Hurlbert

By Marc S. Hurlbert, Ph.D., Executive Director, Avon Foundation Breast Cancer Crusade The field of breast cancer has witnessed remarkable progress due to dedicated biotechnology and academic scientists, advocates, patients, nurses and physicians. Sixty years ago, a woman diagnosed with early stage breast cancer had less than a 55 percent chance of living 10 years, while today those odds are greater than 85 percent. We have made great advances in detecting cancer early with imaging including Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,